Clinical Trials Logo

Gastrointestinal Neoplasms clinical trials

View clinical trials related to Gastrointestinal Neoplasms.

Filter by:

NCT ID: NCT03889626 Not yet recruiting - Neoplasms Clinical Trials

The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer

Start date: March 22, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and tolerability of the maintenance treatment of Apatinib/Capecitabine after fluorouracil and platinum based first-line chemotherapy in advanced gastric cancer.

NCT ID: NCT03866525 Recruiting - Solid Tumor Clinical Trials

OH2 Oncolytic Viral Therapy in Solid Tumors

Start date: April 2, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II study evaluates the safety and efficacy of OH2 as single agent or in combination with HX008, an anti-PD-1 antibody, in patients with malignant solid tumors (gastrointestinal cancers, head and neck cancers, soft tissue sarcomas). OH2 is an oncolytic virus developed upon genetic modifications of the herpes simplex virus type 2 strain HG52, allowing the virus to selectively replicate in tumors. Meanwhile, the delivery of the gene encoding human granulocyte macrophage colony-stimulating factor (GM-CSF) may induce a more potent antitumor immune response.

NCT ID: NCT03862378 Recruiting - Clinical trials for Gastrointestinal Cancer

Prediction of Intra-abdominal Infectious Complication by Drainage Fluid Analysis

APPEAL-GC
Start date: January 1, 2019
Phase:
Study type: Observational [Patient Registry]

In our previous study, a nomogram model was established to predict intra-abdominal infectious complications after gastrointestinal surgery. This model was based on the clinical data and the drainage fluid cytokine levels, and it received an AUC >0.9. In this study, validation of this nomogram is planned to be conducted in this prospective cohort study.

NCT ID: NCT03858855 Completed - Skin Cancer Clinical Trials

Inhaled Essential Oil Effect on Common QOL Concerns During Cancer Treatment

Start date: February 18, 2019
Phase: N/A
Study type: Interventional

This single-blind, randomized controlled trial studies how well inhaled essential oils work for common quality of life concerns in patients who are undergoing cancer treatment such as chemotherapy, targeted therapy, and/or immunotherapy given through the vein (intravenously). Aromatherapy using essential oils, such as ginger essential oil, German chamomile essential oil, and bergamot essential oil, may improve quality of life issues such as nausea, anxiety, loss of appetite, and fatigue in patients undergoing treatment for cancer.

NCT ID: NCT03858712 Completed - Breast Cancer Clinical Trials

EHR-embedded OCDT in Breast or GI Cancer

Start date: March 13, 2019
Phase: N/A
Study type: Interventional

This is research study is for participants with advanced breast or gastrointestinal cancer who have been taking oral chemotherapy medication (Oral Cancer Directed Therapy). This study is to help researchers better understand gaps in assessing oral chemotherapy patient toxicity at home, adherence to treatment and integrate toxicity/adherence reporting.

NCT ID: NCT03850912 Active, not recruiting - Gynecologic Cancer Clinical Trials

Symptom Management Implementation of Patient Reported Outcomes in Oncology

SIMPRO
Start date: July 25, 2019
Phase: N/A
Study type: Interventional

Deficits in the management of common symptoms cause substantial morbidity for cancer patients.Because the health care delivery system is structured to be reactive and not proactive, there are missed opportunities to optimize symptom control. Growth in Internet access and proliferation of smartphones has created an opportunity to re-engineer cancer care delivery. Electronic symptom tracking and feedback is a promising strategy to improve symptom control. Electronic patient reported outcome (ePRO) monitoring of cancer symptoms has been shown to decrease symptom burden, improve quality of life, reduce acute care and even extend survival. SIMPRO will use functioning ePRO prototypes to create and refine the electronic symptom management system eSyM

NCT ID: NCT03833700 Active, not recruiting - Clinical trials for Colorectal Neoplasms

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

Start date: March 5, 2019
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to assess the safety and tolerability of E7386 in participants with solid tumor including CRC.

NCT ID: NCT03828266 Recruiting - Clinical trials for Gastrointestinal Cancer

Prediction of Abdominal Complications After GastroEnterological Surgery

PACAGE
Start date: January 1, 2019
Phase:
Study type: Observational [Patient Registry]

The aim of this multi-centered study is to understand the epidemiology of infectious complications after gastrointestinal surgery in China. In total, 17 centers from China will prospectively register their patients undergo gastric or colorectal surgeries. Patient demographic data, operation information, and postoperative data including the infectious complications and the outcomes will be registered. We expect to include 2000 gastric and 2000 colorectal patients within one year and the study is expected to be finished in 2020.

NCT ID: NCT03812796 Recruiting - Cancer Clinical Trials

Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE)

EMERGE
Start date: January 11, 2019
Phase: Phase 2
Study type: Interventional

A multicenter phase II non-randomised trial assessing the efficacy of domatinostat (4SC-202) plus avelumab in patients with GI cancer

NCT ID: NCT03807518 Completed - Clinical trials for Exercise Intervention

Pre- and Post-Operative Exercise Program in Upper Gastrointestinal Cancers

PERIOP-OG
Start date: March 1, 2019
Phase: N/A
Study type: Interventional

Esophageal and gastric cancers are a considerable health burden. In the past 10 years the 5-year survival for both cancers has doubled. This is due to a number of factors including advances in neo adjuvant and adjuvant chemotherapy and radiotherapy. However, physical fitness significantly declines as a result of neo adjuvant an adjuvant therapy. From studies in other cancers it is known that peri operative training improves physical fitness, yet there is little research into its effects in those with upper gastrointestinal cancers. The aim of this study is to assess the effect of a pre-and post operative training program on patients with upper gastrointestinal cancers on their physical fitness and consequently their optimism, quality of life and post operative morbidity.